Skip to main contentAI and Advanced
/
MANKIND · NSEMarket ticker unavailable · configure an authorised index feed
MA
NSE · Equity shares · Biotechnology & Drugs-34.50 · -1.51%
Mankind Pharma MANKIND
NSE:INR 2,246
BSE:INR 2,430.9
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for MANKIND
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 2,280.5
Day rangeINR 2,246 — INR 2,300.7
52-week rangeINR 1,909.7 — INR 2,674
Volume6.51 L
Market cap1.00 L
P/E51.44
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)14,277.64
Net Income (INR Cr)1,912.93
Rev Growth (5 Year %)18.1
EPS Growth (5 Year %)7.94
P/E Ratio51.44
EPS48.83
Research path: Interpret Mankind Pharma's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
MANKINDMankind Pharma1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 28,079.53 | 27,759.53 | 11,963.25 |
| Cash Equivalents | 160.39 | 150.58 | 118.96 |
| Other Liabilities Total | 278.59 | 175.06 | 146.09 |
| Accrued Expenses | 519.07 | 462.98 | Not available |
| Long Term Debt | 2,821.03 | 5,525.82 | 24.54 |
| Common Stock Total | 41.28 | 41.26 | 40.06 |
| Other Current Assets Total | 819.75 | 56.57 | 82.49 |
| Total Assets | 28,079.53 | 27,759.53 | 11,963.25 |
| Current Portof LT Debt/Capital Leases | 2,597.4 | 275.53 | 23.12 |
| Cash | 231.3 | 256.78 | 263.05 |
| Total Equity | 16,300.34 | 14,332.39 | 9,363.09 |
| Long Term Investments | 475.97 | 525.54 | 316.38 |
| Retained Earnings(Accumulated Deficit) | 16,259.06 | 11,279.75 | 9,270.84 |
| Total Common Shares Outstanding | 41.28 | 41.26 | 40.06 |
| Tangible Book Valueper Share Common Eq | 4.04 | -55.35 | 191.72 |
| Goodwill Net | 6,492.63 | 6,492.63 | 20.02 |
| Total Liabilities | 11,779.19 | 13,427.14 | 2,600.17 |
| Total Debt | 6,311.54 | 8,511.45 | 207.17 |
| Short Term Investments | 1,864.46 | 2,077.78 | 3,004.49 |
| Cashand Short Term Investments | 2,256.15 | 2,485.14 | 3,386.5 |
| Total Receivables Net | 1,733.82 | 2,224.66 | 1,449.73 |
| Notes Payable/Short Term Debt | 821.48 | 2,695.7 | 151.47 |
| Deferred Income Tax | 1,839.98 | 1,812.51 | 89.07 |
| Accounts Receivable-Trade Net | 1,729.51 | 1,538.34 | 848.28 |
| Property/Plant/Equipment Total-Net | 3,614.34 | 3,213.95 | 3,138.69 |
| Minority Interest | 260.71 | 235.79 | 212.7 |
| Total Current Liabilities | 6,507.25 | 5,663.56 | 2,119.73 |
| Total Inventory | 2,144.48 | 2,160.78 | 1,589.11 |
| Accounts Payable | 1,341.33 | 1,133.4 | 1,102.99 |
| Other Currentliabilities Total | 1,227.97 | 1,095.95 | 842.15 |
| Total Long Term Debt | 2,892.66 | 5,540.22 | 32.58 |
| Intangibles Net | 9,641.11 | 10,123.57 | 1,663.04 |
| Other Long Term Assets Total | 382.99 | 148.42 | 110.89 |
| Note Receivable-Long Term | 518.29 | 267.15 | 146.01 |
| Total Current Assets | 6,954.2 | 6,988.27 | 6,568.23 |
| Capital Lease Obligations | 71.63 | 14.4 | 8.04 |
| Accumulated Depreciation Total | Not available | -1,164.56 | -963.39 |
| Other Equity Total | Not available | 3.84 | 10.07 |
| Prepaid Expenses | Not available | 61.12 | 60.39 |
| Additional Paid-In Capital | Not available | 3,007.54 | 42.12 |
| Property/Plant/Equipment Total-Gross | Not available | 4,072.38 | 3,894.98 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio3.77
Price to Sale Ratio7.03
Growth
Debt 5Yr CAGR %92.2
Margins
Operating Margin 12m19.02
Operating Margin 5y Avg20.15
Net Profit Margin 12m14.03
Net Profit Margin 5y16.23
Yield
Dividend Yield %0
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk28.52
Analyst consensus
ConsensusBuy
Consensus score2.19
Analyst opinions16
Strong Sell count0
Sell count2
Hold count4
Buy count5
Strong Buy count5
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 72.63%
- FII
- 9.45%
- MF
- 10.87%
- Other
- 7.05%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Mankind Pharma divests Broadway Hospitality for ₹49 Cr, plans €5 Million Netherlands unit - scanx.tradeMarket news · 14 Jul 2026, 6:25 am
Mankind Pharma divests Broadway Hospitality for ₹49 Cr, plans €5 Million Netherlands unit scanx.trade
799MPL26A Bond Profile — Key Metrics - TradingViewMarket news · 13 Jul 2026, 9:26 pm
799MPL26A Bond Profile — Key Metrics TradingView
Mankind Pharma to set up Netherlands subsidiary for R&D investments - Indian Pharma PostMarket news · 13 Jul 2026, 12:48 pm
Mankind Pharma to set up Netherlands subsidiary for R&D investments Indian Pharma Post
Mankind Pharma Ltd is Rated Hold - MarketsMojoMarket news · 13 Jul 2026, 10:24 am
Mankind Pharma Ltd is Rated Hold MarketsMojo
Analysts Are Updating Their Mankind Pharma Limited (NSE:MANKIND) Estimates After Its Yearly Results - simplywall.stMarket news · 13 Jul 2026, 8:24 am
Analysts Are Updating Their Mankind Pharma Limited (NSE:MANKIND) Estimates After Its Yearly Results simplywall.st
Pharma Majors Shift Focus to Chronic Care as Markets Grow - WhalesbookMarket news · 12 Jul 2026, 6:03 am
Pharma Majors Shift Focus to Chronic Care as Markets Grow Whalesbook
Corporate actions
Events
- annual General MeetingAGM
- board MeetingsQuarterly Results
- board MeetingsAudited Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- dividendRs.1.0000 per share(100%)Interim Dividend
- annual General MeetingAGM
- board MeetingsQuarterly Results & Interim Dividend
Rusaka Markets Community
Discussion and sentiment for Mankind Pharma
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It also offers pet care, crop protection solutions, and veterinary care. It offers healthcare solutions for a range of healthcare needs with a portfolio that includes anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/central nervous system, vitamins, minerals and nutrients, derma, fertility, and respiratory therapies. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, Rivotril, and others. Its subsidiaries include Lifestar Pharma Private Limited, Magnet Labs Private Limited, Jaspack Industries Private Limited, and others.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- MANKIND
- BSE Code
- 543904
Questions
Stock FAQ
What is the symbol and ISIN of Mankind Pharma?
Mankind Pharma has the symbol MANKIND and ISIN - INE634S01028.
What is the current price of Mankind Pharma?
Mankind Pharma is currently trading at INR 2,246.00.
What are the year high and year low of Mankind Pharma?
Mankind Pharma has a year high of INR 2,674.00 and a year low of INR 1,909.70.
What is the market capitalization of Mankind Pharma?
Mankind Pharma has a market capitalization of INR 1.00 lakh crore.
What is the P/E ratio of Mankind Pharma?
Mankind Pharma has a P/E ratio of 51.44.
What is the dividend yield of Mankind Pharma?
Mankind Pharma has a dividend yield of 0.00%.
How is the financial performance of Mankind Pharma based on revenue, net income, and EPS?
Mankind Pharma has revenue of INR 14,277.64 crore, net income of INR 1,912.93 crore, and EPS of INR 51.99.
What is the book value of Mankind Pharma?
Mankind Pharma has a book value of NA.
What is the debt-to-equity ratio of Mankind Pharma?
Mankind Pharma has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Mankind Pharma?
Mankind Pharma has a price-to-book ratio of NA and a price-to-sales ratio of 7.03.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.